Pharmaceutical companies are deploying artificial intelligence to make billion-dollar drug development decisions, but no single executive is accountable when those choices go wrong. Algorithms are selecting which cancer targets deserve research investment, ranking thousands of chemical compounds for efficacy, and determining which patient populations get enrolled in clinical trials. Yet governance structures designed for human decision-making have not caught up with the speed and scale of AI-driven choices.

Where Is AI Making the Biggest Decisions in Drug Development?

AI systems are now embedded at three critical junctures in the drug discovery pipeline, each carrying enormous consequences. Understanding these decision points reveals why accountability has become urgent.

• Target Selection: Machine learning models trained on genomic, proteomic, and clinical datasets identify which biological mechanisms are worth pursuing. These models carry embedded assumptions about disease causes and data quality, yet their confidence scores often lack transparency about which populations the training data represents.
• Compound Prioritization: Generative chemistry models produce novel molecular structures and rank them for predicted safety and effectiveness. What once took chemists years of iterative synthesis can now be proposed computationally in days, but speed does not guarantee wisdom when human reviewers operate downstream of a black box.
• Trial Design and Patient Stratification: AI identifies which patient populations will most likely respond to a therapy, determining both who benefits from drug development and who bears the risks of early-stage testing. When these decisions rely on incomplete or historically biased datasets, the consequences fall directly on real patients.

The problem is structural. When a drug fails or causes harm, accountability becomes circular. The chief data officer points to the chief scientific officer, who points to model developers, who say they built a tool and scientists make the decisions. No pharmaceutical company has appointed an executive solely responsible for AI-driven drug decisions.

What Are the Governance Gaps That Create Liability Risk?

Current regulatory frameworks were not designed for AI-assisted discovery. The FDA's guidance on AI in drug development does not cover discovery tools. The European Medicines Agency (EMA) offers thoughtful guidance but it is nonbinding. Billions of dollars flow through this governance vacuum.

"The goal is not to slow AI down. The efficiency gains are real, the potential to compress drug development timelines is profound, and the promise of AI-discovered therapies for rare and neglected diseases is one of the most compelling humanitarian arguments in modern medicine. Rather, the goal is to ensure that as AI accelerates the machine of drug development, we have deliberate mechanisms for human accountability threaded through every critical junction," stated Guadalupe Hayes-Mota, director of bioethics at the Markkula Center for Applied Ethics.

Guadalupe Hayes-Mota, Director of Bioethics, Markkula Center for Applied Ethics

Board members face two compelling reasons to act now. The fiduciary case is straightforward: any board that approved a digital transformation strategy without also approving an AI accountability framework has an incomplete risk picture. Litigation scenarios involving drug failures traceable to flawed AI decisions are not hypothetical; plaintiff attorneys are already modeling them. The strategic case is equally compelling. Companies that establish rigorous AI governance frameworks now can hold a durable competitive advantage when the FDA inevitably moves from guidance to mandatory requirements.

How to Build AI Accountability Into Drug Development

Establishing accountability does not require slowing innovation. Instead, it requires deliberate mechanisms at every critical decision point. Here are the steps pharmaceutical boards should take immediately:

• Name Specific Accountability: Assign a named individual responsible for reviewing and signing off on each AI-assisted decision in the critical path. This creates clear responsibility rather than diffused accountability across departments.
• Document Model Provenance: Require transparency about what data trained each model, what architecture was used, and how validation was performed. This documentation must be available to regulators or in legal proceedings.
• Audit for Bias Systematically: Make bias auditing standard practice with particular attention to populations underrepresented in training data. Models trained predominantly on data from European ancestry cohorts, for example, carry confidence scores that do not reflect their limitations in other populations.
• Track and Review Overrides: Document when humans override AI recommendations and escalate patterns that emerge. This creates a record of decision-making and identifies when models consistently fail in specific scenarios.
• Report AI Risk to the Board: Include AI risk disclosure alongside financial and operational risk in governance calendars. Board-level reporting ensures oversight at the appropriate level of organizational authority.

These steps are not technically difficult. They are organizationally difficult because they require executives to acknowledge that their AI systems are decision-makers, and that acknowledgment carries responsibility.

What Does the Market Growth Tell Us About AI's Role in Drug Discovery?

The pharmaceutical industry is betting heavily on AI. The global AI in biotechnology market was valued at USD 4.13 billion in 2025 and is projected to reach USD 26.94 billion by 2035, growing at a compound annual rate of 20.6 percent. This explosive growth reflects genuine efficiency gains. Industry surveys show over 70 percent of pharmaceutical and biotech companies are actively funding AI-enabled platforms to drive drug discovery and clinical development.

The numbers justify the investment. Generative AI reduces molecular design time by 25 percent and cuts medical writing time significantly. AI-driven biotech programs are projected to account for 30 percent or more of new drug pipelines by the end of 2026, signaling a structural shift in how medicines are discovered and developed. AI-enabled platforms deliver two to three times faster target identification compared with traditional research methods, and they reduce clinical trial timelines by 20 to 30 percent, with patient recruitment shortened by nearly 40 percent.

Yet this rapid adoption has outpaced governance. The market growth underscores why accountability frameworks are urgent. As AI becomes standard practice in drug discovery, the stakes of flawed decisions grow proportionally.

What Questions Should Boards Be Asking Right Now?

Pharmaceutical boards need to move beyond passive acceptance of AI tools and engage directly with governance. The specific questions they should ask are:

• System Inventory: Which AI systems are embedded in the critical path for target selection, compound ranking, and trial design, and who specifically owns accountability for each one?
• Data Quality: What data was used to train these models, and has that data been audited for bias, completeness, and population representation?
• Override Processes: Is there a documented process for overriding an AI recommendation, and are those overrides tracked, reviewed, and escalated when patterns emerge?
• Liability Documentation: How would the company demonstrate to a regulator or a jury the decision-making chain behind a compound that caused harm?
• Cross-Functional Review: Has the AI governance framework been reviewed by the scientific advisory board, ethics committee, and audit committee, or only by the team that built the systems?

The algorithm that selected a cancer target is not accountable. Nor is the compound ranking model or the trial stratification system. But the board members that approved the strategy funding these systems are unambiguously responsible. The question is whether they know it yet.